What is CRDF's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CRDF.

Stock Ratings / Health Care / CRDF / options

NMRA (34) CSBR (20) CGTX (35) GRML (29) ⌘ Pro Terminal →

Cardiff Oncology Inc. (CRDF) Options Positioning, Max Pain & Unusual Sweeps

$0.84 -5.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.83

Cardiff Oncology Inc. (CRDF) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $69.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRDF Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRDF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cardiff Oncology Inc. (NASDAQ: CRDF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $0.84 (-5.09% 1D, market cap $69.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRDF ranks #931 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRDF compare to NMRA and CSBR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDF carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMRA (Neumora Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $69.0M) and CSBR (Champions Oncology Inc.) posts a E grade (20/100 RQD, P/E N/A, ROIC -26.9%, cap $66.9M). Among the 5-stock peer group, CRDF leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRDF?

▼

Per CRDF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213037), Cardiff Oncology Inc. generated $593.0K in revenue (-13.2% YoY), -$45.9K in net income, and -$38.0M in free cash flow against $61.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.83 (-1.11%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRDF)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (25/100 Composite)

🔍 WHY CRDF SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (24% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 38.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.04-14.4% Next Q

Q2 (-2Q)

Grade E$0.89-10.1% Next Q

Q3 (-1Q)

Grade E$0.80+5% Next Q

Current

Grade E$0.84-10.7% Hist 90D α

Trajectory: E (33) → E (25)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRDF Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRDF currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.08) and Max Pain ($0.88) forces dealer call-delta covering toward $3.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRDF• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRDF Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 25%NO 75%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CRDF)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CRDF.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRDF)

✓Walkthrough of CRDF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRDF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.09%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.91H $0.91L $0.84C $0.84VOL 126.9K

RES: $1.44SUP: $0.77SMA50: $1.08SMA200: $1.43

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRDF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRDF Butterfly Map → + Track CRDF →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -13.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRDF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRDF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRDF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRDF)

Health Care Rank #931 of 1016 ⚔️ NMRA vs CRDF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRDF vs. NMRA, CSBR, CGTX, GRML)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cardiff Oncology Inc. (CRDF) ranks #931 by composite RQD confidence (25/100, grade E) and #698 by equity capitalization ($69.2M). Within this direct 5-issuer industry benchmark cohort, CRDF leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with CRDF at 25/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRDF ACTIVE Cardiff Oncology Inc.	E	25/100	—	—	-35.0%	-5.09%	$69.2M	Benchmark Subject
NMRA Neumora Therapeutics Inc.	E	34/100	—	—	-35.0%	+34.99%	$69.0M	/nmra-vs-crdf →
CSBR Champions Oncology Inc.	E	20/100	—	48.0%	-26.9%	0.00%	$66.9M	/csbr-vs-crdf →
CGTX Cognition Therapeutics Inc.	D-	35/100	—	—	-35.0%	+1.63%	$66.4M	/cgtx-vs-crdf →
GRML Greenland Mines Ltd.	E	29/100	—	—	-35.0%	-12.88%	$62.7M	/grml-vs-crdf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001213037

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cardiff Oncology Inc. (CRDF) reported GAAP revenue of $593.0K (-13.2% vs. FY2024 revenue of $683.0K , and +21.5% cumulative change since FY2023) , GAAP net income of -$45.9K, operating cash flow of -$37.9M, and free cash flow of -$38.0M (-0.5% YoY). On the balance sheet, CRDF closed FY2025 with $61.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$593.0K	-$45.9K	-$37.9M	-$38.0M	$61.9M	—
FY2024 (FY)	2024-12-31	$683.0K	-$45.4K	-$37.7M	-$37.8M	$97.2M	—
FY2023 (FY)	2023-12-31	$488.0K	-$41.4K	-$30.9M	-$30.9M	—	—

3. CRDF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRDF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CRDF compare to NMRA and CSBR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CRDF?

Where is CRDF trading relative to its 50-day, 200-day, and 52-week technical levels?

CRDF last traded at $0.84 (-5.09% on volume of 467,452 shares), positioning the stock -22.22% below its 50-day simple moving average ($1.08) and -41.26% below its 200-day simple moving average ($1.43). Across its 52-week range of $0.76 to $3.31, CRDF sits at the 3.1% percentile with a 14-day RSI of 38.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.94).

Direct Sub-Reports: CRDF RQD Cockpit CRDF 12M Forecast CRDF Earnings & Move CRDF Dividends & DRIP CRDF Insiders & 13F CRDF Whale Options CRDF Profit Sankey CRDF News & Why

ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CRDF — Cardiff Oncology Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:45:37Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

CRDF scores 41/100 with a letter grade of D- and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 5/20. Return on invested capital is -35% and FCF yield is 0%. For an investor, this indicates the business is not currently generating returns on the capital it deploys, so value would depend on future developments rather than present cash generation.
Whale 13F Flow: 15/20. The rating cites institutional accumulation and options positioning.
Insider Conviction: 3/20. The rating cites SEC Form 4 and Congressional PTR cluster flow at a low score, which an investor should read as limited insider-side confidence signals.
Macro Regime Fit: 11/20. Beta is 1.0 and the rating notes sector sensitivity. The stock moves in line with the broad market on this measure, with no defensive cushion indicated.
Forensic Balance Sheet: 7/20. Altman Z-Score is 2.5, Piotroski F-Score is 1 of 9, and Debt/Equity is 0.5. The weak Piotroski reading points to poor financial-health signals across the nine tests.

Upside drivers in the data are limited to the pipeline and institutional interest; the valuation tradeoff is that a $70.9M market capitalization with negative operating margin (-60%) and negative ROIC leaves little earnings support for the current price. The rating's overall posture is cautious.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cardiff Oncology Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company operates as a clinical-stage entity. Revenue is minimal, reported at $0. —

Operating losses are consistently large relative to revenue, and the operating margin is -60%. Net margin is -7.7% and gross margin is 0%. ROIC is -35%. Cash declined from $51.5M in FY 2024 to $17.5M in FY 2025, a reduction of $34.0M in one year. The Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, . The Debt/Equity ratio is 0.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Institutional accumulation and options positioning earn the highest RQD pillar score (15/20), signaling some institutional interest despite weak fundamentals. With Fundamental Cash Engine at 5/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 4/20, sustained execution supports upside toward the top of the $0.76 – $3.31 52-week range.
🐻 Primary Bear Case: With FY 2025 operating income of -$49.0M against revenue of $0.6M, a Piotroski F-Score of 1/9, and cash falling from $51.5M to $17.5M, the balance sheet is under pressure. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The most relevant second-order consideration visible in the data is the approved increase in authorized shares to 300 million, which a prospective investor could track for dilution effects on per-share value given the $0.89 price and $70.9M market capitalization.

Key Question #1: What is the company's cash runway given cash of $17.5M at FY 2025 against FCF of -$38.0M?
Key Question #2: What is the debt balance behind the reported Debt/Equity of 0.5, and what are the maturities?
Key Question #3: What specific clinical programs drive the pipeline, and what are their timelines and milestones?

CRDF Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cardiff Oncology Inc. (CRDF) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRDF Debate Forum (3) ↓

🟡 MARKET WIRE StockInvest.us • 20h ago

Cardiff Oncology Stock Price Forecast. Should You Buy CRDF?

StockInvest.us report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

All trial patients still enrolled have had over 18 months of treatment. Cardiff Oncology names an interim medical chief.

Stock Titan report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

CRDF Q3'26 Earnings: EPS estimate is (0.14) USD

TradingView report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Cardiff Oncology Inc. (CRDF) Slides 7.21% to $0.90 as Shares Test Lower Support Zone - Bollinger Expansion

https://www.siam.in/ report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

CRDF Q2 2026 Earnings: Narrower-Than-Expected Loss as Cardiff Oncology Advances Clinical-Stage Pipeline - Guidance Accuracy Score

https://www.dars.gov.et/ report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Minichart • 1d ago

Cardiff Oncology Holders Approve Doubling Authorized Common Stock to 300 Million Shares

Minichart report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Cardiff Oncology, Inc. (CRDF) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Cardiff Oncology, Inc. Stock Price Today | CRDF Live Chart & News

Traders Union report covering Cardiff Oncology Inc. (CRDF) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRDF Bull vs. Bear Conversation Board — What's Your Call at $0.84?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRDF 🐻 33% BEARISH CONVICTION

QU QuantViper Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $1.14 (+28.1%)

📌 Pinned Debate

Institutional accumulation and options positioning earn the highest RQD pillar score (15/20), signaling some institutional interest des

Picked up a starter position in CRDF in my $100K Virtual Cash book at $0.89. Institutional accumulation and options positioning earn the highest RQD pillar score (15/20), signaling some institutional interest despite weak fundamentals.. Trading inside a $0.76–$3.31 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

SectorRotator 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression Valuation Discipline 🐻 BEARISH 🎯 Target: $0.72 (-19.1%)

Spot @ $0.89

With FY 2025 operating income of -$49.0M against revenue of $0.6M, a Piotroski F-Score of 1/9, and cash falling from $51.5M to $17.5M,

Careful chasing CRDF at $0.89. With FY 2025 operating income of -$49.0M against revenue of $0.6M, a Piotroski F-Score of 1/9, and cash falling from $51.5M to $17.5M, the balance sheet is under pressure.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.72 on multiple compression.